Literature DB >> 26268659

CXCL9 Regulates TGF-β1-Induced Epithelial to Mesenchymal Transition in Human Alveolar Epithelial Cells.

Sarah L O'Beirne1, Sinead M Walsh1, Aurélie Fabre2, Carlota Reviriego3, Julie C Worrell3, Ian P Counihan1, Robert V Lumsden3, Jennifer Cramton-Barnes3, John A Belperio4, Seamas C Donnelly1, Denise Boylan3, Joëlle Marchal-Sommé5, Rosemary Kane3, Michael P Keane6.   

Abstract

Epithelial to mesenchymal cell transition (EMT), whereby fully differentiated epithelial cells transition to a mesenchymal phenotype, has been implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF). CXCR3 and its ligands are recognized to play a protective role in pulmonary fibrosis. In this study, we investigated the presence and extent of EMT and CXCR3 expression in human IPF surgical lung biopsies and assessed whether CXCR3 and its ligand CXCL9 modulate EMT in alveolar epithelial cells. Coexpression of the epithelial marker thyroid transcription factor-1 and the mesenchymal marker α-smooth muscle actin and CXCR3 expression was examined by immunohistochemical staining of IPF surgical lung biopsies. Epithelial and mesenchymal marker expression was examined by quantitative real-time PCR, Western blotting, and immunofluorescence in human alveolar epithelial (A549) cells treated with TGF-β1 and CXCL9, with Smad2, Smad3, and Smad7 expression and cellular localization examined by Western blotting. We found that significantly more cells were undergoing EMT in fibrotic versus normal areas of lung in IPF surgical lung biopsy samples. CXCR3 was expressed by type II pneumocytes and fibroblasts in fibrotic areas in close proximity to cells undergoing EMT. In vitro, CXCL9 abrogated TGF-β1-induced EMT. A decrease in TGF-β1-induced phosphorylation of Smad2 and Smad3 occurred with CXCL9 treatment. This was associated with increased shuttling of Smad7 from the nucleus to the cytoplasm where it inhibits Smad phosphorylation. This suggests a role for EMT in the pathogenesis of IPF and provides a novel mechanism for the inhibitory effects of CXCL9 on TGF-β1-induced EMT.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26268659      PMCID: PMC4777321          DOI: 10.4049/jimmunol.1402008

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

Review 1.  The myofibroblast in pulmonary fibrosis.

Authors:  Sem H Phan
Journal:  Chest       Date:  2002-12       Impact factor: 9.410

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis.

Authors:  Marco Chilosi; Venerino Poletti; Alberto Zamò; Maurizio Lestani; Licia Montagna; Paola Piccoli; Serena Pedron; Manuela Bertaso; Aldo Scarpa; Bruno Murer; Alessandra Cancellieri; Roberta Maestro; Gianpietro Semenzato; Claudio Doglioni
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

4.  Incomplete expression of epithelial-mesenchymal transition markers in idiopathic pulmonary fibrosis.

Authors:  Patrizia Morbini; Simona Inghilleri; Ilaria Campo; Tiberio Oggionni; Michele Zorzetto; Maurizio Luisetti
Journal:  Pathol Res Pract       Date:  2011-07-27       Impact factor: 3.250

Review 5.  Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.

Authors:  M Selman; T E King; A Pardo
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

6.  Role of the chemokine receptors CXCR3 and CCR4 in human pulmonary fibrosis.

Authors:  Patrizia Pignatti; Giuseppe Brunetti; Dania Moretto; Mona-Rita Yacoub; Marco Fiori; Bruno Balbi; Antonella Balestrino; Gabriella Cervio; Stefano Nava; Gianna Moscato
Journal:  Am J Respir Crit Care Med       Date:  2005-10-20       Impact factor: 21.405

7.  Regulation of pulmonary fibrosis by chemokine receptor CXCR3.

Authors:  Dianhua Jiang; Jiurong Liang; Jennifer Hodge; Bao Lu; Zhou Zhu; Shuang Yu; Juan Fan; Yunfei Gao; Zhinan Yin; Robert Homer; Craig Gerard; Paul W Noble
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

8.  Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization.

Authors:  M Loetscher; P Loetscher; N Brass; E Meese; B Moser
Journal:  Eur J Immunol       Date:  1998-11       Impact factor: 5.532

9.  Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans.

Authors:  Hermann E Wasmuth; Frank Lammert; Mirko Moreno Zaldivar; Ralf Weiskirchen; Claus Hellerbrand; David Scholten; Marie-Luise Berres; Henning Zimmermann; Konrad L Streetz; Frank Tacke; Sonja Hillebrandt; Petra Schmitz; Hildegard Keppeler; Thomas Berg; Edgar Dahl; Nikolaus Gassler; Scott L Friedman; Christian Trautwein
Journal:  Gastroenterology       Date:  2009-04-01       Impact factor: 22.682

10.  An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.

Authors:  Laura Lasagni; Michela Francalanci; Francesco Annunziato; Elena Lazzeri; Stefano Giannini; Lorenzo Cosmi; Costanza Sagrinati; Benedetta Mazzinghi; Claudio Orlando; Enrico Maggi; Fabio Marra; Sergio Romagnani; Mario Serio; Paola Romagnani
Journal:  J Exp Med       Date:  2003-06-02       Impact factor: 14.307

View more
  8 in total

1.  Deficiency of α7 nicotinic acetylcholine receptor attenuates bleomycin-induced lung fibrosis in mice.

Authors:  Peiyu Sun; Ling Li; Caiqi Zhao; Mengyao Pan; Zhikang Qian; Xiao Su
Journal:  Mol Med       Date:  2017-03-06       Impact factor: 6.354

2.  H. sinensis mycelium inhibits epithelial-mesenchymal transition by inactivating the midkine pathway in pulmonary fibrosis.

Authors:  Li Lu; Haiyan Zhu; Hailin Wang; Huaping Liang; Yayi Hou; Huan Dou
Journal:  Front Med       Date:  2021-04-27       Impact factor: 4.592

3.  Role of CXCL16 in BLM-induced epithelial-mesenchymal transition in human A549 cells.

Authors:  Xiangyuan Liu; Qingrui Yang; Zhenzhen Ma; Chunyan Ma; Qingfeng Zhang; Yang Bai; Kun Mu
Journal:  Respir Res       Date:  2021-02-06

4.  Inhibition of renal fibrosis with a human CXCL9-derived glycosaminoglycan-binding peptide.

Authors:  Fariba Poosti; Mohammad Ayodhia Soebadi; Helena Crijns; Alexandra De Zutter; Mieke Metzemaekers; Nele Berghmans; Vincent Vanheule; Maarten Albersen; Ghislain Opdenakker; Jo Van Damme; Ben Sprangers; Paul Proost; Sofie Struyf
Journal:  Clin Transl Immunology       Date:  2022-02-02

5.  Regulation and characterization of tumor-infiltrating immune cells in breast cancer.

Authors:  Qile Dai; Weimiao Wu; Amei Amei; Xiting Yan; Lingeng Lu; Zuoheng Wang
Journal:  Int Immunopharmacol       Date:  2020-11-19       Impact factor: 4.932

Review 6.  Mechanisms of TGFβ-Induced Epithelial-Mesenchymal Transition.

Authors:  Aristidis Moustakas; Carl-Henrik Heldin
Journal:  J Clin Med       Date:  2016-06-29       Impact factor: 4.241

7.  Sirtuin 6 inhibits epithelial to mesenchymal transition during idiopathic pulmonary fibrosis via inactivating TGF-β1/Smad3 signaling.

Authors:  Kunming Tian; Panpan Chen; Zhiping Liu; Shutian Si; Qian Zhang; Yong Mou; Lianyong Han; Qin Wang; Xue Zhou
Journal:  Oncotarget       Date:  2017-05-09

8.  Thalidomide Inhibits TGF-β1-induced Epithelial to Mesenchymal Transition in Alveolar Epithelial Cells via Smad-Dependent and Smad-Independent Signaling Pathways.

Authors:  Xian-Long Zhou; Peng Xu; Hai-Hua Chen; Yan Zhao; Jun Shen; Cheng Jiang; Shan Jiang; Shao-Zhou Ni; Bing Xu; Lei Li
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.